CAU
LXRX icon

Caxton Associates (UK)’s Lexicon Pharmaceuticals LXRX Stock Holding History

Caxton Associates (UK)’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-71,027
Closed -$81.7K – 914
2025
Q4 		$81.7K Buy
+71,027
New +$97.6K ﹤0.01% 750

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Caxton Associates (UK)'s LXRX Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 71,027 shares — an estimated $81.7K sold.

Caxton Associates (UK) first reported a position in LXRX in Q4 2025 and held it in 1 quarter. The position peaked at $81.7K in Q4 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 71,027 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $81.7K.
  • Caxton Associates (UK) first reported a position in Lexicon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Lexicon Pharmaceuticals position peaked at $81.7K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.